MEK2 Protein

MEK2 Protein (MAP2K2)

Overview

MEK2 (also known as MAP2K2 or MAP Kinase/Erk Kinase 2) is a dual-specificity protein kinase that serves as a critical intermediate in the mitogen-activated protein kinase (MAPK) signaling cascade[@mekneuro2021]. As one of two MEK isoforms (MEK1/MAP2K1 and MEK2/MAP2K2), MEK2 specifically phosphorylates and activates the extracellular signal-regulated kinases ERK1 and ERK2, which are central to numerous cellular processes including proliferation, differentiation, survival, and synaptic plasticity[@erkneuronal2023].

The MAPK signaling pathway represents one of the most evolutionarily conserved signal transduction cascades in eukaryotic cells, and its dysregulation has been strongly implicated in the pathogenesis of multiple neurodegenerative diseases including Alzheimer's disease (AD) and Parkinson's disease (PD)[@mektherapyneuro2023]. MEK2, along with its paralog MEK1, occupies a pivotal position in this cascade, receiving input from RAF kinases upstream and passing signals to ERK effectors downstream.

MEK2 Protein (MAP2K2)

Overview

MEK2 (also known as MAP2K2 or MAP Kinase/Erk Kinase 2) is a dual-specificity protein kinase that serves as a critical intermediate in the mitogen-activated protein kinase (MAPK) signaling cascade[@mekneuro2021]. As one of two MEK isoforms (MEK1/MAP2K1 and MEK2/MAP2K2), MEK2 specifically phosphorylates and activates the extracellular signal-regulated kinases ERK1 and ERK2, which are central to numerous cellular processes including proliferation, differentiation, survival, and synaptic plasticity[@erkneuronal2023].

The MAPK signaling pathway represents one of the most evolutionarily conserved signal transduction cascades in eukaryotic cells, and its dysregulation has been strongly implicated in the pathogenesis of multiple neurodegenerative diseases including Alzheimer's disease (AD) and Parkinson's disease (PD)[@mektherapyneuro2023]. MEK2, along with its paralog MEK1, occupies a pivotal position in this cascade, receiving input from RAF kinases upstream and passing signals to ERK effectors downstream.

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">MEK2 Protein (MAP2K2)</th></tr>
<tr><td><strong>Protein Name</strong></td><td>MEK2</td></tr>
<tr><td><strong>Gene Symbol</strong></td><td>MAP2K2</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P36507](https://www.uniprot.org/uniprot/P36507)</td></tr>
<tr><td><strong>Gene ID</strong></td><td>[5605](https://www.ncbi.nlm.nih.gov/gene/5605)</td></tr>
<tr><td><strong>Chromosomal Location</strong></td><td>19p13.3</td></tr>
<tr><td><strong>PDB IDs</strong></td><td>1S3J, 3E0N, 3EO1</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>44.2 kDa</td></tr>
<tr><td><strong>Protein Length</strong></td><td>400 amino acids</td></tr>
<tr><td><strong>Subcellular Location</strong></td><td>Cytoplasm, Nucleus</td></tr>
<tr><td><strong>Protein Family</strong></td><td>MEK dual-specificity kinases</td></tr>
<tr><td><strong>EC Number</strong></td><td>2.7.12.2</td></tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
</div>

Structure

Catalytic Domain Architecture

MEK2 possesses a characteristic bilobal kinase domain structure common to all eukaryotic protein kinases, comprising an N-terminal lobe (residues 35-120) rich in β-strands and a C-terminal lobe (residues 121-280) predominantly α-helical[@mekstructure2018]. The active site resides in the deep cleft between these two lobes, where ATP binding and phosphate transfer occur. The dual-specificity nature of MEK2 allows it to phosphorylate both tyrosine and threonine residues on its substrates, a property uniquely shared with MEK1 among mammalian kinases.

The activation loop of MEK2 (residues 218-238) contains the critical dual phosphorylation sites S222 and S226 (and the corresponding residues in MEK1), which must be phosphorylated for full catalytic activity. This phosphorylation is typically catalyzed by RAF kinases (BRAF, RAF1/CRAF, or ARAF) in response to growth factors, cytokines, or cellular stress.

Allosteric Regulation

MEK2 demonstrates sophisticated allosteric regulation through multiple mechanisms. The N-terminal regulatory region (residues 1-34) contains a putative nuclear export signal (NES) and contributes to protein-protein interactions. Additionally, MEK2 can form homodimers and heterodimers with MEK1, with dimerization enhancing catalytic activity through trans-activation[@mekstructure2018].

Normal Function

MAPK Cascade Position

MEK2 functions as the central gateway between RAF kinases and ERK kinases in the canonical MAPK cascade:

RAF → MEK1/2 → ERK1/2 → Transcription Factors → Cellular Response

When activated by growth factors or other stimuli, RAF kinases phosphorylate MEK2 at S222 and S226, converting it to an active form. Active MEK2 then phosphorylates ERK1 (MAPK1/MAPK3) at specific threonine and tyrosine residues (T202/Y204 for ERK1, T185/Y187 for ERK2), enabling ERK to phosphorylate numerous downstream targets[@mapkapoptosis2021].

Neuronal Functions

In neurons, the MEK2-ERK pathway subserves critical functions:

Calcium Signaling Integration

MEK2 receives input from multiple signaling pathways beyond RAF kinases. Calcium influx through NMDA receptors and voltage-gated calcium channels can activate Ras-GRF proteins, which in turn activate RAF-MEK-ERK signaling[@mekcalcium2024]. This integration allows neuronal activity to modulate the MAPK cascade.

Role in Neurodegenerative Diseases

Alzheimer's Disease

Multiple lines of evidence implicate MEK2 dysregulation in AD pathogenesis:

Amyloid-beta Effects: Amyloid-beta (Aβ) oligomers, widely considered toxic drivers of AD, activate several kinases that feed into the MEK2-ERK pathway. Aβ-induced ERK activation has been documented in neurons and glia, contributing to both beneficial adaptive responses and pathological cascades[@brafalzheimer2024].

Tau Phosphorylation: The MEK2-ERK pathway can phosphorylate tau protein at multiple sites implicated in neurofibrillary tangle formation. ERK2 (and by extension MEK2 activity) can directly phosphorylate tau at S202, T231, and S396, sites critical for tangle development[@mekneuro2021].

Synaptic Dysfunction: Chronic over-activation of MEK2-ERK signaling in AD may contribute to synaptic dysfunction. While acute ERK activation supports synaptic plasticity, prolonged activation can lead to AMPA receptor internalization and synaptic depression.

Neuroinflammation: Activated microglia in AD release inflammatory cytokines that can activate MEK2-ERK signaling in neurons and glia. This creates feedback loops that may amplify neuroinflammation[@mekcopd2024].

Parkinson's Disease

Protein Aggregation: The MEK2-ERK pathway is perturbed in PD models. Alpha-synuclein aggregation can activate MAPK signaling, including MEK2-ERK[@raf1parkinson2023]. Interestingly, some studies suggest that moderate MEK inhibition may protect against alpha-synuclein toxicity.

Mitochondrial Dysfunction: Mitochondrial dysfunction is central to PD pathogenesis. MEK2-ERK signaling interacts with mitochondrial quality control pathways, and dysregulation can exacerbate mitochondrial deficits[@mekmitochondrial2023].

Neuroinflammation: As in AD, chronic neuroinflammation in PD involves MEK2-ERK activation in microglia and astrocytes, contributing to dopaminergic neuron loss.

Therapeutic Potential: Recent studies suggest that MEK inhibitors like trametinib may provide neuroprotection in PD models, potentially by normalizing aberrant signaling or reducing neuroinflammation[@trametinibneuro2024].

Other Neurodegenerative Conditions

Amyotrophic Lateral Sclerosis (ALS): MAPK pathway activation, including MEK2-ERK, is observed in ALS spinal cord. The role appears complex, with both protective and toxic effects depending on context.

Frontotemporal Dementia (FTD): MEK2-ERK dysregulation contributes to tau pathology in FTD models.

Huntington's Disease (HD): Mutant huntingtin protein activates MAPK signaling pathways, including MEK2-ERK, contributing to neuronal dysfunction.

Therapeutic Targeting

MEK Inhibitors

Several MEK inhibitors have been developed for cancer therapy and are being investigated for neurodegenerative diseases:

| Drug | Target | Status | Relevant Studies |
|------|--------|--------|------------------|
| Trametinib | MEK1/2 | Approved (oncology) | PD models[@trametinibneuro2024] |
| Selumetinib | MEK1/2 | Approved (oncology) | Pediatric tumors[@selumetinibpediatric2023] |
| Cobimetinib | MEK1/2 | Approved (oncology) | Preclinical neuro |
| Binimetinib | MEK1/2 | Approved (oncology) | Preclinical neuro |

Challenges and Considerations

Blood-Brain Barrier Penetration: Many MEK inhibitors have limited CNS penetration, necessitating development of brain-penetrant analogs.

Dose-Dependent Effects: The relationship between MEK2 inhibition and neuroprotection is biphasic. While excessive inhibition blocks beneficial signaling, moderate inhibition may reduce pathological activation.

Timing: Chronic versus acuteMEK inhibition may have different effects. Early intervention might be more beneficial than treatment at advanced disease stages.

Combination Therapies: MEK inhibitors may be most effective in combination with other targeted therapies addressing different aspects of neurodegeneration.

Preclinical Evidence

Multiple preclinical studies support MEK inhibition as a therapeutic strategy:

• Reduced neuroinflammation in mouse models treated with MEK inhibitors[@mekcopd2024]
• Neuroprotection against MPTP toxicity in PD models
• Reduced amyloid-beta-induced toxicity
• Improved behavioral outcomes in tauopathy models

Key Research Findings

Interactions and Pathway Context

Upstream Regulators

• RAF kinases: BRAF, RAF1 (c-Raf), ARAF phosphorylate and activate MEK2
• Ras GTPases: Activated Ras recruits RAF to the membrane
• Protein phosphatases: PP2A dephosphorylates MEK2, providing negative regulation

Downstream Effectors

• ERK1 (MAPK3): Primary substrate
• ERK2 (MAPK1): Primary substrate
• RSK (Ribosomal S6 kinase): ERK-activated kinase
• MSK1/2: Mitogen- and stress-activated kinases

Interacting Proteins

• MEK1: Forms heterodimers
• ERK1/2: Direct substrates
• KSR (Kinase Suppressor of Ras): Scaffold protein
• 14-3-3 proteins: Binding partners regulating activity

Cross-Links

• [MAP2K2 Gene](/genes/map2k2)
• [MAPK Signaling Pathway](/mechanisms/mapk-signaling-neurodegeneration)
• [ERK1/2 Protein](/proteins/erk1-2-protein)
• [BRAF Protein](/proteins/braf-protein)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Tau Protein](/proteins/tau-protein)
• [Synaptic Plasticity Mechanisms](/mechanisms/synaptic-plasticity)

References